Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options.
Low-density lipoprotein cholesterol (LDL-C) is currently the primary target in the management of dyslipidemia, and statins are first-line pharmacologic interventions. Adjunct therapy such as niacins, fibrates, bile acid sequestrants, or cholesterol absorption inhibitors may be considered to help reduce cardiovascular risk. This review discusses the need for alternative adjunct treatment options and the potential place for omega-3 fatty acids as such. The cardiovascular benefits of fish consumption are attributed to the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and a variety of omega-3 fatty acid products are available with varied amounts of EPA and DHA. The product types include prescription drugs, food supplements, and medical foods sourced from fish, krill, algal and plant oils or purified from these oils. Two prescription omega-3 fatty acids are currently available, omega-3 fatty acid ethyl esters (contains both EPA and DHA ethyl esters), and icosapent ethyl (IPE; contains high-purity EPA ethyl ester). A pharmaceutical containing free fatty acid forms of omega-3 is currently in development. Omega-3 fatty acid formulations containing EPA and DHA have been shown to increase LDL-C levels while IPE has been shown to lower triglyceride levels without raising LDL-C levels, alone or in combination with statin therapy. In addition, recent studies have not been able to demonstrate reduced cardiovascular risk following treatment with fibrates, niacins, cholesterol absorption inhibitors, or omega-3 fatty acid formulations containing both EPA and DHA in statin-treated patients; thus, there remains a need for further cardiovascular outcomes studies for adjunct therapy.
New York University School of Medicine Center for the Prevention of Cardiovascular Disease, 530 First Avenue, Suite 9U, New York, NY 10016, United States. Electronic address: Howard.Weintraub@nyumc.org.
Howard
H
Weintraub
D000818:Animals; D002318:Cardiovascular Diseases / Q000517:prevention & control; D002784:Cholesterol / Q000737:chemistry; D004032:Diet; D004281:Docosahexaenoic Acids / Q000737:chemistry; D050171:Dyslipidemias / Q000178:diet therapy* / Q000188:drug therapy; D015118:Eicosapentaenoic Acid / Q000737:chemistry; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use*; D005396:Fish Products; D005399:Fishes; D006801:Humans; D015228:Hypertriglyceridemia / Q000178:diet therapy* / Q000188:drug therapy; D010938:Plant Oils / Q000737:chemistry; D012306:Risk; D016896:Treatment Outcome
D015525:Fatty Acids, Omega-3; D010938:Plant Oils; D004281:Docosahexaenoic Acids; D002784:Cholesterol; D015118:Eicosapentaenoic Acid
Docosahexaenoic acid; Dyslipidemia; Eicosapentaenoic acid; Fish oil; Omega 3 fatty acid